Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.81 |
| ▸ | RAB9A | P51151 | 3/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716724 | 0.87 | KDM4E (0.68) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL29635245 | 0.87 | KDM4E (0.68) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL12929591 | 0.87 | KDM4E (0.68) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL12929389 | 0.87 | ALDH1A1 (0.77) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL10377442 | 0.85 | KDM4E (0.65) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL9788390 | 0.84 | KDM4E (0.64) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL15976546 | 0.84 | ALDH1A1 (1.00) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL5511035 | 0.83 | SMN1; SMN2 (0.61) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL12929470 | 0.83 | KDM4E (0.62) | KDM4ERAB9ATP53HSD17B10ALDH1A1 | |
| SCHEMBL10375284 | 0.83 | RAB9A (0.62) | KDM4ERAB9ATP53HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384944-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | KDM4E 3872/4885RAB9A 1333/4885TP53 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.